Reports on Endoscopy Findings from Massachusetts General Hospital Provide New Insights (Association of Glucagon-like Peptide Receptor 1 Agonist Therapy With the Presence of Gastric Contents In Fasting Patients Undergoing Endoscopy Under...).

A recent study conducted at Massachusetts General Hospital in Boston, Massachusetts, examined the association between glucagon-like peptide 1 (GLP-1) receptor agonist therapy and the presence of gastric contents in fasting patients undergoing endoscopy. The researchers reviewed the records of esophagogastroduodenoscopy (EGD) procedures performed between 2019 and 2023 and compared patients taking GLP-1 agonists at the time of the procedure with those who started GLP-1 agonist therapy after undergoing EGD. The study found that GLP-1 agonist therapy was associated with an increased incidence of residual gastric contents, potentially posing a higher risk of periprocedural pulmonary aspiration. This research provides new insights into the effects of GLP-1 agonist therapy on fasting patients undergoing endoscopy. [Extracted from the article]

Copyright of Pain & Central Nervous System Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)